Literature DB >> 23939353

Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome.

Ednan K Bajwa1, Jessica A Volk, David C Christiani, R Scott Harris, Michael A Matthay, B Taylor Thompson, James L Januzzi.   

Abstract

OBJECTIVES: Soluble suppression of tumorigenicity-2 is a biomarker of myocardial strain and inflammation. The characteristics of acute respiratory distress syndrome include inflammation and cardiovascular dysfunction. We sought to determine whether plasma soluble suppression of tumorigenicity-2 concentration is associated with outcome and response to conservative fluid management and whether soluble suppression of tumorigenicity-2 concentration discriminates acute respiratory distress syndrome from decompensated heart failure.
DESIGN: A retrospective analysis of the Fluid and Catheter Treatment Trial, a multi-center randomized controlled trial of conservative fluid management in the acute respiratory distress syndrome, as well as of a cohort of patients with decompensated heart failure.
SETTING: Twenty acute care hospitals. PATIENTS: Eight hundred twenty-six patients with acute respiratory distress syndrome and 209 patients with acutely decompensated heart failure.
MEASUREMENTS AND MAIN RESULTS: Nonsurvivors had higher day 0 (p < 0.0001) and day 3 (p < 0.0001) soluble suppression of tumorigenicity-2 concentrations. After adjustment for severity of illness, higher soluble suppression of tumorigenicity-2 concentration was associated with mortality, with odds ratioadj 1.47 (95% CI, 0.99-2.20; p = 0.06) at day 0, 2.94 (95% CI, 2.00-4.33; p < 0.0001) at day 3, and 3.63 (95% CI, 2.38-5.53; p < 0.0001) if soluble suppression of tumorigenicity-2 increased between days. Cumulative fluid balance was more positive among patients with higher day 0 (median, 5,212 mL [interquartile range, 200-12,284 mL] vs median, 2,020 mL [interquartile range, -2,034 to 7,091 mL]; p < 0.0001) and day 3 soluble suppression of tumorigenicity-2 (median, 7,678 mL [interquartile range, 2,217-14,278 mL] vs median, 1,492 mL [interquartile range, -2,384 to 6,239 mL]; p < 0.0001). Soluble suppression of tumorigenicity-2 showed excellent discriminative ability between the Fluid and Catheter Treatment Trial and heart failure populations (area under receiver-operating characteristic curve = 0.98; p < 0.0001).
CONCLUSIONS: Higher soluble suppression of tumorigenicity-2 concentrations are associated with worse outcome in acute respiratory distress syndrome and may have value for discriminating acute respiratory distress syndrome from heart failure.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23939353      PMCID: PMC3812317          DOI: 10.1097/CCM.0b013e3182978f91

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  34 in total

1.  Diagnosing acute lung injury in the critically ill: a national survey among critical care physicians.

Authors:  A P J Vlaar; W B Honselaar; J M Binnekade; A B Groeneveld; P E Spronk; M J Schultz; N P Juffermans
Journal:  Acta Anaesthesiol Scand       Date:  2009-08-31       Impact factor: 2.105

2.  Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay.

Authors:  Benjamin Dieplinger; James L Januzzi; Martin Steinmair; Christian Gabriel; Werner Poelz; Meinhard Haltmayer; Thomas Mueller
Journal:  Clin Chim Acta       Date:  2009-08-20       Impact factor: 3.786

3.  ST2 gene induced by type 2 helper T cell (Th2) and proinflammatory cytokine stimuli may modulate lung injury and fibrosis.

Authors:  Shunji Tajima; Masashi Bando; Shoji Ohno; Yukihiko Sugiyama; Katsuhisa Oshikawa; Shin-ichi Tominaga; Kouichi Itoh; Toshinori Takada; Eiichi Suzuki; Fumitake Gejyo
Journal:  Exp Lung Res       Date:  2007-03       Impact factor: 2.459

4.  Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome.

Authors:  Ednan K Bajwa; James L Januzzi; Michelle N Gong; B Taylor Thompson; David C Christiani
Journal:  Crit Care Med       Date:  2008-08       Impact factor: 7.598

5.  Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury.

Authors:  Lorraine B Ware; Tatsuki Koyama; D Dean Billheimer; William Wu; Gordon R Bernard; B Taylor Thompson; Roy G Brower; Theodore J Standiford; Thomas R Martin; Michael A Matthay
Journal:  Chest       Date:  2009-10-26       Impact factor: 9.410

6.  Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders.

Authors:  Carolyn S Calfee; Mark D Eisner; Lorraine B Ware; B Taylor Thompson; Polly E Parsons; Arthur P Wheeler; Anna Korpak; Michael A Matthay
Journal:  Crit Care Med       Date:  2007-10       Impact factor: 7.598

7.  Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.

Authors:  Shafiq U Rehman; Thomas Mueller; James L Januzzi
Journal:  J Am Coll Cardiol       Date:  2008-10-28       Impact factor: 24.094

8.  Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.

Authors:  Marc S Sabatine; David A Morrow; Luke J Higgins; Catherine MacGillivray; Wei Guo; Christophe Bode; Nader Rifai; Christopher P Cannon; Robert E Gerszten; Richard T Lee
Journal:  Circulation       Date:  2008-03-31       Impact factor: 29.690

9.  Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling.

Authors:  Kenjiro Seki; Shoji Sanada; Anastacia Y Kudinova; Matthew L Steinhauser; Vandna Handa; Joseph Gannon; Richard T Lee
Journal:  Circ Heart Fail       Date:  2009-09-22       Impact factor: 8.790

10.  Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.

Authors:  Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more
  21 in total

1.  Critical research on biomarkers: what's new?

Authors:  Matthieu Legrand; James L Januzzi; Alexandre Mebazaa
Journal:  Intensive Care Med       Date:  2013-07-05       Impact factor: 17.440

Review 2.  Interleukin-33 and its Receptor in Pulmonary Inflammatory Diseases.

Authors:  Jing Zhao; Yutong Zhao
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

3.  The evolution of radiographic edema in ARDS and its association with clinical outcomes: A prospective cohort study in adult patients.

Authors:  Daniel Kotok; Libing Yang; John W Evankovich; William Bain; Daniel G Dunlap; Faraaz Shah; Yingze Zhang; Dimitris V Manatakis; Panayiotis V Benos; Ian J Barbash; Sarah F Rapport; Janet S Lee; Alison Morris; Bryan J McVerry; Georgios D Kitsios
Journal:  J Crit Care       Date:  2020-01-13       Impact factor: 3.425

4.  Host-Response Subphenotypes Offer Prognostic Enrichment in Patients With or at Risk for Acute Respiratory Distress Syndrome.

Authors:  Georgios D Kitsios; Libing Yang; Dimitris V Manatakis; Mehdi Nouraie; John Evankovich; William Bain; Daniel G Dunlap; Faraaz Shah; Ian J Barbash; Sarah F Rapport; Yingze Zhang; Rebecca S DeSensi; Nathaniel M Weathington; Bill B Chen; Prabir Ray; Rama K Mallampalli; Panayiotis V Benos; Janet S Lee; Alison Morris; Bryan J McVerry
Journal:  Crit Care Med       Date:  2019-12       Impact factor: 7.598

5.  B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS.

Authors:  Matthew W Semler; Annis M Marney; Todd W Rice; Hui Nian; Chang Yu; Arthur P Wheeler; Nancy J Brown
Journal:  Chest       Date:  2016-03-23       Impact factor: 9.410

6.  Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.

Authors:  Sachiko Seo; Jeffrey Yu; Isaac C Jenkins; Wendy M Leisenring; Terry Steven-Ayers; Jane M Kuypers; Meei-Li Huang; Keith R Jerome; Michael Boeckh; Sophie Paczesny
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-06       Impact factor: 5.742

7.  Plasma Concentrations of Soluble Suppression of Tumorigenicity-2 and Interleukin-6 Are Predictive of Successful Liberation From Mechanical Ventilation in Patients With the Acute Respiratory Distress Syndrome.

Authors:  Jehan W Alladina; Sean D Levy; Kathryn A Hibbert; James L Januzzi; R Scott Harris; Michael A Matthay; B Taylor Thompson; Ednan K Bajwa
Journal:  Crit Care Med       Date:  2016-09       Impact factor: 7.598

8.  Relationship of soluble ST2 to pulmonary hypertension severity in patients undergoing cardiac resynchronization therapy.

Authors:  Jonathan Beaudoin; Jackie Szymonifka; Zachary Lavender; Roderick C Deaño; Qing Zhou; James L Januzzi; Jagmeet P Singh; Quynh A Truong
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

9.  Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure.

Authors:  Jehan Alladina; Sean D Levy; Josalyn L Cho; Kelsey L Brait; Sowmya R Rao; Alexander Camacho; Kathryn A Hibbert; R Scott Harris; Benjamin D Medoff; James L Januzzi; B Taylor Thompson; Ednan K Bajwa
Journal:  Am J Respir Crit Care Med       Date:  2021-05-15       Impact factor: 21.405

10.  Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration.

Authors:  Ourania S Kotsiou; Rajesh M Jagirdar; Eleftherios D Papazoglou; Chrissi Hatzoglou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Inflammation       Date:  2019-12       Impact factor: 4.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.